These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 34625562

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
    Houvenaeghel G, Cohen M, Raro P, De Troyer J, de Lara CT, Gimbergues P, Gauthier T, Faure-Virelizier C, Vaini-Cowen V, Lantheaume S, Regis C, Darai E, Ceccato V, D'Halluin G, Del Piano F, Villet R, Jouve E, Beedassy B, Theret P, Gabelle P, Zinzindohoue C, Opinel P, Marsollier-Ferrer C, Dhainaut-Speyer C, Colombo PE, Lambaudie E, Tallet A, Boher JM, Others investigators (SERC trial group).
    BMC Cancer; 2018 Nov 21; 18(1):1153. PubMed ID: 30463611
    [Abstract] [Full Text] [Related]

  • 3. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
    Riedel F, Heil J, Feisst M, Moderow M, von Au A, Domschke C, Michel L, Schaefgen B, Golatta M, Hennigs A.
    Breast Cancer Res Treat; 2020 Nov 21; 184(2):627-636. PubMed ID: 32816190
    [Abstract] [Full Text] [Related]

  • 4. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, Győrffy B, Kásler M, Mátrai Z.
    Eur J Surg Oncol; 2017 Apr 21; 43(4):672-679. PubMed ID: 28139362
    [Abstract] [Full Text] [Related]

  • 5. The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases.
    Houvenaeghel G, de Nonneville A, Chopin N, Classe JM, Mazouni C, Chauvet MP, Reyal F, Tunon de Lara C, Jouve E, Rouzier R, Daraï E, Gimbergues P, Coutant C, Azuar AS, Villet R, Crochet P, Rua S, Bannier M, Cohen M, Boher JM.
    Cancer Med; 2023 Feb 21; 12(4):4023-4032. PubMed ID: 36127853
    [Abstract] [Full Text] [Related]

  • 6. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
    Tvedskov TF.
    Dan Med J; 2012 Jul 21; 59(7):B4475. PubMed ID: 22759850
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
    Riedel F, Heil J, Feißt M, Rezai M, Moderow M, Sohn C, Schütz F, Golatta M, Hennigs A.
    Breast Cancer Res Treat; 2019 Sep 21; 177(2):457-467. PubMed ID: 31236814
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?
    Sávolt A, Polgár C, Musonda P, Mátrai Z, Rényi-Vámos F, Tóth L, Kásler M, Péley G.
    Clin Breast Cancer; 2013 Oct 21; 13(5):364-70. PubMed ID: 23773380
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
    Poodt IGM, Spronk PER, Vugts G, van Dalen T, Peeters MTFDV, Rots ML, Kuijer A, Nieuwenhuijzen GAP, Schipper RJ.
    Ann Surg; 2018 Dec 21; 268(6):1084-1090. PubMed ID: 28742702
    [Abstract] [Full Text] [Related]

  • 17. Are the ACOSOG Z0011 Trial Findings Being Applied to Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy?
    Kantor O, Pesce C, Liederbach E, Wang CH, Winchester DJ, Yao K.
    Breast J; 2017 Sep 21; 23(5):554-562. PubMed ID: 28295828
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
    Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Morrow M, Hunt KK.
    Ann Surg; 2016 Sep 21; 264(3):413-20. PubMed ID: 27513155
    [Abstract] [Full Text] [Related]

  • 20. Omission of axillary dissection according to ACOSOG Z0011: impact on adjuvant treatment recommendations.
    Aigner J, Smetanay K, Hof H, Sinn HP, Sohn C, Schneeweiss A, Marmé F.
    Ann Surg Oncol; 2013 May 21; 20(5):1538-44. PubMed ID: 23389469
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.